FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T16:27:56.023Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
Product / business disclosures (FY 2025)
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Non Cash Royalty Revenue Related To Sale Of Future Royalties$54.93M
License Collaboration And Other Revenue$300,000
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Geographic disclosures (FY 2025)
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
$10.13M
vs Estimate
$10.43M
Missed
NKTR Analyst Ratings
Consensus Rating
Buy
Based on 10 analysts
Strong Buy
1
Buy
9
Hold
2
Sell
0
Strong Sell
0
Average Price Target
$141.40
+252.4% upside
Low
$50.00
Current
$40.12
High
$192.00
NKTR Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
Period
Low
Avg
High
# Analysts
Quarter ending Sep 2026
$-2.93
$-2.10
$-1.63
10
Quarter ending Dec 2026
$-3.40
$-2.70
$-2.06
10
Quarter ending Mar 2027
$-3.09
$-2.75
$-2.54
8
Quarter ending Jun 2027
$-2.97
$-2.65
$-2.45
8
Annual
Period
Low
Avg
High
# Analysts
FY 2026
$-9.54
$-8.09
$-6.83
11
FY 2027
$-18.69
$-10.25
$-3.82
11
Revenue Estimates
Quarterly
Period
Low
Avg
High
# Analysts
Quarter ending Sep 2026
$9.58M
$10.26M
$11.04M
10
Quarter ending Dec 2026
$9.92M
$10.53M
$11.08M
10
Quarter ending Mar 2027
$9.68M
$10.27M
$11.25M
9
Quarter ending Jun 2027
$9.49M
$10.08M
$11.04M
9
Annual
Period
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
